IL308627A - Methods for the treatment of post-infectious autoimmune diabetes - Google Patents

Methods for the treatment of post-infectious autoimmune diabetes

Info

Publication number
IL308627A
IL308627A IL308627A IL30862723A IL308627A IL 308627 A IL308627 A IL 308627A IL 308627 A IL308627 A IL 308627A IL 30862723 A IL30862723 A IL 30862723A IL 308627 A IL308627 A IL 308627A
Authority
IL
Israel
Prior art keywords
methods
autoimmune diabetes
treating post
infectious autoimmune
post infectious
Prior art date
Application number
IL308627A
Other languages
English (en)
Hebrew (he)
Inventor
Francisco Leon
Original Assignee
Provention Bio Inc
Francisco Leon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc, Francisco Leon filed Critical Provention Bio Inc
Publication of IL308627A publication Critical patent/IL308627A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL308627A 2021-05-24 2022-05-24 Methods for the treatment of post-infectious autoimmune diabetes IL308627A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192414P 2021-05-24 2021-05-24
PCT/US2022/030780 WO2022251258A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes
US17/752,650 US20220372146A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes

Publications (1)

Publication Number Publication Date
IL308627A true IL308627A (en) 2024-01-01

Family

ID=84104472

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308627A IL308627A (en) 2021-05-24 2022-05-24 Methods for the treatment of post-infectious autoimmune diabetes

Country Status (10)

Country Link
US (1) US20220372146A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347021A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521164A (cg-RX-API-DMAC7.html)
KR (1) KR20240023522A (cg-RX-API-DMAC7.html)
CN (1) CN117794572A (cg-RX-API-DMAC7.html)
AU (1) AU2022283272A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219473A1 (cg-RX-API-DMAC7.html)
IL (1) IL308627A (cg-RX-API-DMAC7.html)
MX (1) MX2023013849A (cg-RX-API-DMAC7.html)
WO (1) WO2022251258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20230382993A1 (en) * 2022-05-24 2023-11-30 Provention Bio, Inc. Methods and compositions for preventing or delaying type 1 diabetes
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
JP2009544761A (ja) * 2006-06-14 2009-12-17 マクロジェニクス,インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
JP7137696B2 (ja) * 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
WO2021035054A1 (en) * 2019-08-20 2021-02-25 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
KR20230092863A (ko) * 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) * 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20230382993A1 (en) * 2022-05-24 2023-11-30 Provention Bio, Inc. Methods and compositions for preventing or delaying type 1 diabetes

Also Published As

Publication number Publication date
JP2024521164A (ja) 2024-05-28
US20220372146A1 (en) 2022-11-24
CA3219473A1 (en) 2022-12-01
WO2022251258A1 (en) 2022-12-01
AU2022283272A1 (en) 2023-12-07
EP4347021A4 (en) 2025-04-23
EP4347021A1 (en) 2024-04-10
CN117794572A (zh) 2024-03-29
MX2023013849A (es) 2023-12-08
KR20240023522A (ko) 2024-02-22

Similar Documents

Publication Publication Date Title
PT3684377T (pt) Métodos de tratamento de infeção de hepatite b
GB2587032B (en) Method for designing accelerator hardware
SG11201803578RA (en) A treatment method for silicon-containing wastewater and the utilization method thereof, and a method for preparing a molecular sieve and the system thereof
SG10201608532PA (en) Methods, apparatus and devices for authenticating a call session
PL3317335T3 (pl) Sposób oczyszczania zanieczyszczonych polimerów
PL3943153T3 (pl) Układ leczenia wychwytem neutronów
IL272791A (en) Methods for treating muscular dystrophy
PL3849190T3 (pl) Sposób projektowania składni oraz przyrząd do przeprowadzania kodowania z wykorzystaniem składni
IL286653A (en) Methods for treating muscular dystrophy with Casimersen
PL3317334T3 (pl) Sposób oczyszczania zanieczyszczonych polimerów
ZA202001141B (en) Zeolite after treatment method
SG10202000757YA (en) Confirming method
GB2580513B (en) Method for preparing modified molecular sieve
IL277754B1 (en) A method for the production of spirochetal-converted cyclic ketoanols
IL264485B (en) A method for the production of cyclic ketones converted in spirochetal
IL234801B (en) Adjustable ring for blood vessels, means for treating sfs syndrome, an implantable kit including said ring, a pattern and method for making the ring
GB202303660D0 (en) Proteoform specific process validation
HUE048933T2 (hu) Szavazási eljárás láncolt aláírásokkal
GB201806736D0 (en) Method for virus purification
ZA202106319B (en) Two-stage method for recovering halogenated hydrocarbons
GB202111184D0 (en) Methods
EP2838249A4 (en) METHOD, DEVICE AND SYSTEM FOR PROCESSING A LANGUAGE CALL
ZA201505598B (en) Method, processing modules and system for executing an executable code
EP3560571C0 (fr) Procede de purification de fructose
HK40109640A (en) Methods for treating post infectious autoimmune diabetes